Antagonism of the cholecystokinin 2 (CCK2) G-protein coupled receptor (GPCR) represents an attractive pharmaceutical target with a potential role in treating gastric-acid related conditions, as well as gastrointestinal and pancreatic cancers. Result: 27 diverse compounds with activities below 10μM.
Please click here.

To view the full case study please click here.